サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1609994

小児臨床試験市場規模、シェア、動向分析レポート：フェーズ別、研究設計別、適応症別、地域別、セグメント予測、2025年～2030年

Pediatric Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase III), By Study Design (Treatment Studies, Observational Studies), By Indication, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 120 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.96円
小児臨床試験市場規模、シェア、動向分析レポート：フェーズ別、研究設計別、適応症別、地域別、セグメント予測、2025年～2030年
出版日: 2024年11月12日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

小児臨床試験市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の小児臨床試験市場規模は2030年までに269億9,000万米ドルに達し、2025～2030年のCAGRは5.25%で拡大すると推定されています。

同市場は、世界の小児臨床試験件数の増加により成長しています。BMCジャーナルによると、2008年1月から2010年12月の間に7,029件の小児臨床試験が登録されました。一方、2017年1月から2019年12月の間に、登録された小児臨床試験の数は11,738件であり、これは確かに産業全体の試験総数の大幅な急増を反映しています。COVID-19小児患者に対する治療選択肢はパンデミック開始当初は限られていたが、そのおかげで2020年5月、FDAは成人と小児のCOVID-19治療に使用可能なVeklury（remdesivir）の緊急使用承認（EUA）を付与しました。

同様に、Convalescent plasmaも小児と成人のCOVID-19治療にFDAからEUAを取得しました。このような規制当局の動きは、小児臨床試験の需要を促進すると考えられます。さらに、小児疾患に関連する臨床研究を支援するための複数の政府機関による取り組みが増加していることも、市場の成長をさらに後押ししています。例えば、2022年3月、米国国立がんラボは小児腫瘍の分子特性化イニシアチブを立ち上げました。このイニシアチブはNCIのChildhood Cancer Data Initiativeを通じて提供されるもので、小児腫瘍を研究する研究者間のデータ共有と新しいデータの収集を促進するために結成されました。

加えて、小児がんの有病率が増加していることも、市場だけでなく腫瘍学セグメントの成長を支える重要な要因です。例えば、米国臨床腫瘍学会（ASCO）が2022年2月に述べたように、米国では2022年末までに推定1万470人の15歳以下の小児と約5,480人の15歳から19歳の10代の若者ががんと診断されます。WHOは、下痢、マラリア、肺炎、敗血症が生後1ヵ月から9歳までの子どもの主要死因であるとしています。したがって、市場の成長にプラスの影響を与える可能性が高いです。感染症の高い負担とは別に、かなりの数の幼児たちが糖尿病に苦しんでいます。

例えば、米国CDCによると、米国では2018年に2,690万人以上が糖尿病と診断され、その中には21万人の20～25歳以下の小児と青年が含まれています。商業的には、COVID-19ワクチンは18歳以上の成人への接種が中心であったため、18歳以下の小児に高い罹患リスクがあった。ClinicalTrial.GOVによると、2022年5月4日現在、小児患者を対象としたCOVID-19の治療・診断のための研究が1,000件以上行われています。小児におけるCOVID-19の負担は、2021年から小児科向けのCOVID-19ワクチン試験の需要を促進すると考えられます。

小児臨床試験市場レポートハイライト

  • 観察研究セグメントは予測期間中にかなりの成長率を示すと予想されます。これらの試験は、治療によるまれな転帰を調査し、異常な副作用を検出するために実施されます。このような要因が、小児科における観察研究の需要を促進しています。
  • フェーズIIセグメントは2024年に最大のシェアを占めました。第II相試験は多くの小児科被験者で構成され、さらにこの相の試験は他の相の試験よりも複雑です。このような要因が、このセグメントの高いシェアに寄与しています。
  • 治療セグメント別では、小児がん患者の割合が高いことから、がん領域がその他領域に次いで2024年に最も大きなシェアを占め、臨床試験の需要に寄与しています。
  • アジア太平洋は人口が多く、新しい治療への需要に貢献していることから、予測期間中に最も速いCAGRを記録すると予測されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 小児臨床試験市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場展望
    • 関連/付随市場展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 市場分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19の影響分析

第4章 小児臨床試験市場：フェーズ別、推定・動向分析

  • セグメントダッシュボード
  • 世界の小児臨床試験市場：フェーズ変動分析
  • 2018～2030年のフェーズ別の世界の小児臨床試験の規模と傾向の分析
  • フェーズI
  • フェーズII
  • フェーズIII
  • フェーズIV

第5章 小児臨床試験市場：研究設計別、推定・動向分析

  • セグメントダッシュボード
  • 世界の小児臨床試験市場、研究設計変動分析
  • 2018～2030年の研究設計別の世界の小児臨床試験の規模と傾向の分析
  • 治療研究
  • 観察研究

第6章 小児臨床試験市場：適応症別、推定・動向分析

  • セグメントダッシュボード
  • 世界の小児臨床試験市場、適応症変動分析
  • 2018～2030年の適応症別の世界の小児臨床試験の規模と傾向の分析
  • 感染症
  • 腫瘍学
  • 自己免疫/炎症
  • 呼吸器疾患
  • 精神疾患
  • その他

第7章 小児臨床試験市場：地域別、推定・動向分析

  • 地域別市場シェア分析、2024年と2030年
  • 地域別市場ダッシュボード
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 企業分類
  • 企業市況分析、2024年
  • 企業プロファイル
    • ICON plc
    • Syneos Health
    • Medpace
    • Thermo Fisher Scientific Inc.
    • Premier Research
    • ICON plc
    • Laboratory Corporation of America
    • QPS Holdings.
    • Pfizer Inc.
    • The Emmes Company, LLC
    • IQVIA Inc.
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 4 Global Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 5 Global Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 6 Global Pediatric Clinical Trials, by Region, 2018 - 2030 (USD Million)
  • Table 7 North America Pediatric Clinical Trials, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 9 North America Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 10 Global Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 11 U.S. Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 12 U.S. Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 13 U.S. Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 14 Canada Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 15 Canada Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 16 Canada Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 17 Mexico Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 18 Mexico Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 19 Mexico Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 20 UK Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 21 UK Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 22 UK Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 23 Germany Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 24 Germany Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 25 Germany Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 26 France Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 27 France Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 28 France Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 29 Italy Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 30 Italy Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 31 Italy Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 32 Spain Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 33 Spain Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 34 Spain Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 35 Sweden Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 36 Sweden Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 37 Sweden Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 38 Norway Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 39 Norway Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 40 Norway Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 41 Denmark Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 42 Denmark Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 43 Denmark Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 44 India Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 45 India Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 46 India Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 47 China Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 48 China Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 49 China Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 50 Japan Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 51 Japan Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 52 Japan Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 53 India Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 54 India Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 55 India Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 56 Australia Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 57 Australia Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 58 Australia Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 59 Thailand Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 60 Thailand Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 61 Thailand Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 62 South Korea Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 63 South Korea Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 64 South Korea Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 65 Brazil Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 66 Brazil Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 67 Brazil Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 68 Argentina Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 69 Argentina Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 70 Argentina Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 71 Saudi Arabia Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 72 Saudi Arabia Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 73 Saudi Arabia Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 74 UAE Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 75 UAE Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 76 UAE Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)
  • Table 77 Kuwait Pediatric Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 78 Kuwait Pediatric Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 79 Kuwait Pediatric Clinical Trials, by Indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig 1. Information Procurement
  • Fig 2. Primary Research Pattern
  • Fig 3. Market Research Approaches
  • Fig 4. Value Chain-Based Sizing & Forecasting
  • Fig 5. Market Formulation & Validation
  • Fig 6. Pediatric Clinical Trials, Market Segmentation
  • Fig 7. Market Driver Relevance Analysis (Current & Future Impact)
  • Fig 8. Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig 9. Porter's Five Forces Analysis
  • Fig 10. PESTEL Analysis
  • Fig 11. Regional Marketplace: Key Takeaways
  • Fig 12. Global Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 13. Global Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 14. Global Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 15. Global Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 16. Global Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 17. Global Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 18. Global Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 19. Global Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 20. Global Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 21. Global Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 22. Global Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 23. North America Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 24. North America Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 25. North America Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 26. North America Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 27. North America Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 28. North America Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 29. North America Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 30. North America Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 31. North America Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 32. North America Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 33. North America Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 34. U.S. Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 35. U.S. Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 36. U.S. Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 37. U.S. Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 38. U.S. Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 39. U.S. Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 40. U.S. Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 41. U.S. Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 42. U.S. Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 43. U.S. Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 44. U.S. Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 45. Canada Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 46. Canada Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 47. Canada Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 48. Canada Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 49. Canada Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 50. Canada Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 51. Canada Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 52. Canada Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 53. Canada Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 54. Canada Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 55. Canada Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 56. Mexico Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 57. Mexico Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 58. Mexico Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 59. Mexico Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 60. Mexico Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 61. Mexico Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 62. Mexico Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 63. Mexico Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 64. Mexico Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 65. Mexico Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 66. Mexico Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 67. UK Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 68. UK Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 69. UK Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 70. UK Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 71. UK Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 72. UK Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 73. UK Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 74. UK Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 75. UK Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 76. UK Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 77. UK Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 78. Germany Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 79. Germany Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 80. Germany Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 81. Germany Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 82. Germany Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 83. Germany Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 84. Germany Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 85. Germany Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 86. Germany Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 87. Germany Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 88. Germany Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 89. France Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 90. France Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 91. France Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 92. France Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 93. France Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 94. France Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 95. France Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 96. France Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 97. France Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 98. France Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 99. France Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 100. Spain Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 101. Spain Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 102. Spain Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 103. Spain Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 104. Spain Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 105. Spain Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 106. Spain Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 107. Spain Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 108. Spain Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 109. Spain Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 110. Spain Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 111. Italy Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 112. Italy Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 113. Italy Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 114. Italy Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 115. Italy Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 116. Italy Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 117. Italy Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 118. Italy Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 119. Italy Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 120. Italy Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 121. Italy Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 122. Denmark Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 123. Denmark Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 124. Denmark Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 125. Denmark Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 126. Denmark Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 127. Denmark Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 128. Denmark Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 129. Denmark Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 130. Denmark Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 131. Denmark Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 132. Denmark Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 133. Sweden Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 134. Sweden Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 135. Sweden Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 136. Sweden Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 137. Sweden Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 138. Sweden Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 139. Sweden Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 140. Sweden Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 141. Sweden Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 142. Sweden Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 143. Sweden Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 144. Norway Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 145. Norway Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 146. Norway Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 147. Norway Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 148. Norway Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 149. Norway Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 150. Norway Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 151. Norway Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 152. Norway Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 153. Norway Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 154. Norway Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 155. Asia Pacific Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 156. Asia Pacific Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 157. Asia Pacific Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 158. Asia Pacific Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 159. Asia Pacific Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 160. Asia Pacific Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 161. Asia Pacific Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 162. Asia Pacific Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 163. Asia Pacific Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 164. Asia Pacific Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 165. Asia Pacific Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 166. Japan Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 167. Japan Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 168. Japan Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 169. Japan Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 170. Japan Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 171. Japan Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 172. Japan Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 173. Japan Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 174. Japan Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 175. Japan Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 176. Japan Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 177. China Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 178. China Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 179. China Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 180. China Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 181. China Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 182. China Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 183. China Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 184. China Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 185. China Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 186. China Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 187. China Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 188. India Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 189. India Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 190. India Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 191. India Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 192. India Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 193. India Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 194. India Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 195. India Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 196. India Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 197. India Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 198. India Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 199. Australia Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 200. Australia Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 201. Australia Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 202. Australia Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 203. Australia Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 204. Australia Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 205. Australia Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 206. Australia Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 207. Australia Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 208. Australia Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 209. Australia Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 210. Thailand Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 211. Thailand Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 212. Thailand Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 213. Thailand Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 214. Thailand Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 215. Thailand Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 216. Thailand Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 217. Thailand Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 218. Thailand Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 219. Thailand Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 220. Thailand Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 221. South Korea Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 222. South Korea Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 223. South Korea Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 224. South Korea Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 225. South Korea Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 226. South Korea Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 227. South Korea Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 228. South Korea Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 229. South Korea Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 230. South Korea Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 231. South Korea Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 232. Latin America Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 233. Latin America Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 234. Latin America Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 235. Latin America Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 236. Latin America Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 237. Latin America Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 238. Latin America Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 239. Latin America Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 240. Latin America Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 241. Latin America Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 242. Latin America Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 243. Brazil Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 244. Brazil Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 245. Brazil Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 246. Brazil Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 247. Brazil Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 248. Brazil Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 249. Brazil Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 250. Brazil Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 251. Brazil Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 252. Brazil Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 253. Brazil Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 254. Argentina Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 255. Argentina Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 256. Argentina Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 257. Argentina Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 258. Argentina Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 259. Argentina Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 260. Argentina Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 261. Argentina Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 262. Argentina Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 263. Argentina Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 264. Argentina Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 265. MEA Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 266. MEA Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 267. MEA Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 268. MEA Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 269. MEA Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 270. MEA Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 271. MEA Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 272. MEA Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 273. MEA Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 274. MEA Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 275. MEA Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 276. South Africa Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 277. South Africa Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 278. South Africa Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 279. South Africa Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 280. South Africa Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 281. South Africa Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 282. South Africa Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 283. South Africa Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 284. South Africa Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 285. South Africa Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 286. South Africa Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 287. Saudi Arabia Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 288. Saudi Arabia Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 289. Saudi Arabia Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 290. Saudi Arabia Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 291. Saudi Arabia Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 292. Saudi Arabia Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 293. Saudi Arabia Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 294. Saudi Arabia Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 295. Saudi Arabia Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 296. Saudi Arabia Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 297. Saudi Arabia Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 298. UAE Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 299. UAE Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 300. UAE Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 301. UAE Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 302. UAE Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 303. UAE Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 304. UAE Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 305. UAE Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 306. UAE Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 307. UAE Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 308. UAE Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
  • Fig 309. Kuwait Pediatric Clinical Trials, for Phase I, 2018 - 2030 (USD Million)
  • Fig 310. Kuwait Pediatric Clinical Trials, for Phase II, 2018 - 2030 (USD Million)
  • Fig 311. Kuwait Pediatric Clinical Trials, for Phase III, 2018 - 2030 (USD Million)
  • Fig 312. Kuwait Pediatric Clinical Trials, For Phase IV, 2018 - 2030 (USD Million)
  • Fig 313. Kuwait Pediatric Clinical Trials, For Treatment Studies, 2018 - 2030 (USD Million)
  • Fig 314. Kuwait Pediatric Clinical Trials, For Observational, 2018 - 2030 (USD Million)
  • Fig 315. Kuwait Pediatric Clinical Trials, For Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig 316. Kuwait Pediatric Clinical Trials, For Oncology, 2018 - 2030 (USD Million)
  • Fig 317. Kuwait Pediatric Clinical Trials, For Respiratory Disorders, 2018 - 2030 (USD Million)
  • Fig 318. Kuwait Pediatric Clinical Trials, For Mental Health Disorders, 2018 - 2030 (USD Million)
  • Fig 319. Kuwait Pediatric Clinical Trials, For Others, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68039-940-1

Pediatric Clinical Trials Market Growth & Trends:

The global pediatric clinical trials market size is estimated to reach USD 26.99 billion by 2030, expanding at a CAGR of 5.25% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is growing on account of the rise in the number of pediatric clinical studies globally. As per the BMC journal, between January 2008 and December 2010, 7,029 pediatric clinical trials were registered. Whereas, between January 2017 and December 2019, the number of registered pediatric clinical trials was 11,738, which certainly reflects a significant surge in the total number of trials across the industry. The treatment options for COVID-19 pediatric patients were limited at the start of the pandemic, owing to which, in May 2020, FDA granted an Emergency Use Authorization (EUA) for Veklury (remdesivir), which could be used for the treatment of COVID-19 in adults and children.

Similarly, Convalescent plasma was also granted an EUA from the FDA for the treatment of children and adults with COVID-19. Such actions by the regulatory agencies are likely to promote the demand for pediatric clinical trials. Furthermore, increasing efforts by several government bodies to support the clinical research pertaining to pediatric diseases has further supported the market growth. For instance, in March 2022, the National Cancer Institute launched the Molecular Characterization Initiative for pediatric tumors. The Initiative is offered through NCI's Childhood Cancer Data Initiative, which was formed to promote data sharing and collection of new data among researchers who study pediatric oncology.

In addition, the increasing prevalence of pediatric cancer is another significant factor supporting the market as well as the oncology segment's growth. For instance, as stated by the American Society of Clinical Oncology (ASCO)in February 2022, in the U.S., an estimated 10,470 children are younger than 15 years of age and about 5,480 teens aged 15 to 19 years will be diagnosed with cancer by the end of 2022. The WHO states that diarrhea, malaria, pneumonia, and sepsis are the leading causes of death among children between the age of 1 month and 9 years The high burden of these diseases is contributing to the demand for new treatment opinions. Thus, is likely to have a positive impact on the market growth. Apart from the high burden of infectious diseases, a significant number of children also suffer from diabetes.

For instance, according to the U.S. CDC, over 26.9 million in the U.S. were diagnosed with diabetes in 2018, which included 210,000 children and adolescents younger than age 20-or 25 years. Commercially, COVID19 vaccines were majorly focused on immunizing adults aged 18 years and above, this created a high risk of disease among children below the age of 18 years. The ClinicalTrial.GOV reports that as on 4th May 2022, over 1000 studies were in the active stage for treating and diagnosing COVID-19 for pediatric patients. The burden of COVID-19 among the kids is likely to promote the demand for COVID-19 vaccine trials for pediatrics from 2021.

Pediatric Clinical Trials Market Report Highlights:

  • The observational segment is expected to witness a considerable growth rate over the forecast period. These studies are done to investigate rare outcomes of the treatment and to detect unusual adverse effects. Such factors are driving the demand for observational studies in pediatrics
  • The Phase II segment accounted for the largest share in 2024. Phase II studies consist of a high number of pediatric subjects; moreover, studies in this phase are more complex than that in other phases. Such factors are contributed to the segment's high share
  • Based on therapeutic area, the oncology segment accounted for the largest share in 2024, after the others segment, owing to the high burden of cancer among the pediatrics, thus contributing to the demand for clinical studies
  • Asia Pacific is projected to witness the fastest CAGR during the forecast years owing to the high population of the region, which contributes to the demand for new treatments

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis
    • 1.6.2. Bottom-up Approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Pediatric Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growth in the Number of Pediatric Clinical Trials
      • 3.2.1.2. Rising Investment in R&D by the Pharmaceutical Companies
      • 3.2.1.3. High Burden of Chronic and Infectious Diseases among Children
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Rising Costs of Clinical Trials
      • 3.2.2.2. Complex Regulatory Landscape
  • 3.3. Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Pediatric Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Pediatric Clinical Trials Market; Phase Movement Analysis
  • 4.3. Global Pediatric Clinical Trials Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
  • 4.4. Phase I
    • 4.4.1. Phase I market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Phase II
    • 4.5.1. Phase II market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Phase III
    • 4.6.1. Phase III market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Phase IV
    • 4.7.1. Phase IV market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pediatric Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Pediatric Clinical Trials Market; Study Design Movement Analysis
  • 5.3. Global Pediatric Clinical Trials Size & Trend Analysis, by Study Design, 2018 to 2030 (USD Million)
  • 5.4. Treatment Studies
    • 5.4.1. Interventional studies market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Observational Studies
    • 5.5.1. Observational studies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Pediatric Clinical Trials Market: Indication Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Pediatric Clinical Trials Market; Indication Movement Analysis
  • 6.3. Global Pediatric Clinical Trials Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 6.4. Infectious Diseases
    • 6.4.1. Infectious diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Oncology
    • 6.5.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Autoimmune/inflammation
    • 6.6.1. Autoimmune/inflammation market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Respiratory Disorders
    • 6.7.1. Respiratory disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Mental Health Disorders
    • 6.8.1. Mental Health Disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. Others
    • 6.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Pediatric Clinical Trials Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. North America
    • 7.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Competitive scenario
      • 7.3.2.3. Regulatory framework
      • 7.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Competitive scenario
      • 7.3.3.3. Regulatory framework
      • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key country dynamics
      • 7.3.4.2. Competitive scenario
      • 7.3.4.3. Regulatory framework
      • 7.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Competitive scenario
      • 7.4.5.3. Regulatory framework
      • 7.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Competitive scenario
      • 7.4.6.3. Regulatory framework
      • 7.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Competitive scenario
      • 7.4.7.3. Regulatory framework
      • 7.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Competitive scenario
      • 7.4.8.3. Regulatory framework
      • 7.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key country dynamics
      • 7.4.9.2. Competitive scenario
      • 7.4.9.3. Regulatory framework
      • 7.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Thailand
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Competitive scenario
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Company Market Position Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. ICON plc
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Service benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. Syneos Health
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Service benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Medpace
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Service benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Thermo Fisher Scientific Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Service benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Premier Research
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Service benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. ICON plc
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Service benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Laboratory Corporation of America
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Service benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. QPS Holdings.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Service benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Pfizer Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Service benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. The Emmes Company, LLC
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Service benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. IQVIA Inc.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Service benchmarking
      • 8.3.11.4. Strategic initiatives